Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.

IF 1.9 4区 医学 Q2 OPHTHALMOLOGY
Nevo Kovalis, Shmuel Graffi, Shadi Safuri, Yinon Shapira, Geulah Ben-David, Michael Mimouni
{"title":"Duration of Bare Sclera Pterygium Surgery Combined with Mitomycin C with and Without Tranexamic Acid: A Randomized Double-Blind Controlled Trial.","authors":"Nevo Kovalis, Shmuel Graffi, Shadi Safuri, Yinon Shapira, Geulah Ben-David, Michael Mimouni","doi":"10.1089/jop.2024.0068","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Purpose:</i></b> To evaluate the efficacy of subconjunctival tranexamic acid (TXA) in reducing intraoperative bleeding, shortening surgery duration, and improving postoperative outcomes in pterygium surgery. <b><i>Methods:</i></b> In this double-blind, randomized controlled trial, 50 eyes of 50 patients undergoing pterygium surgery were randomly assigned to receive either subconjunctival injection of 0.25 mL of 5% TXA (TXA group, <i>n</i> = 25) or an equivalent volume of saline (control group, <i>n</i> = 25). Baseline characteristics, including age, gender, working environment, allergies, preoperative logMAR best-corrected visual acuity, and systemic anticoagulant or antiplatelet therapy, were similar between the groups. The primary outcome measures were intraoperative bleeding, surgery duration, and the number of eye spears used. Secondary outcome measures included postoperative visual acuity and pterygium recurrence rates at 3 years post-surgery. <b><i>Results:</i></b> No significant differences were observed between the TXA group and the control group in terms of surgery duration (445.3 ± 94.8 s vs. 423.5 ± 80.6 s, <i>P</i> = 0.40), the number of eye spears used (3.5 ± 2.4 vs. 3.5 ± 2.6, <i>P</i> = 0.97), or the weight of absorbed blood (1.94 ± 1.40 grams vs. 1.90 ± 1.25 grams, <i>P</i> = 0.91). Additionally, there were no significant differences in postoperative visual acuity (0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR, P = 0.39) or pterygium recurrence rates at 3 years post-surgery (8.0% vs. 4.4%, <i>P</i> = 0.60). Subconjunctival TXA injection was safe, with no reported adverse events or complications associated with its use. <b><i>Conclusion:</i></b> Subconjunctival injection of TXA did not significantly reduce intraoperative bleeding, shorten surgery duration, or improve postoperative outcomes in pterygium surgery. The intervention was safe and well-tolerated, but further research is warranted to explore alternative interventions or modifications to the surgical technique that may improve outcomes in pterygium surgery.</p>","PeriodicalId":16689,"journal":{"name":"Journal of Ocular Pharmacology and Therapeutics","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ocular Pharmacology and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jop.2024.0068","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the efficacy of subconjunctival tranexamic acid (TXA) in reducing intraoperative bleeding, shortening surgery duration, and improving postoperative outcomes in pterygium surgery. Methods: In this double-blind, randomized controlled trial, 50 eyes of 50 patients undergoing pterygium surgery were randomly assigned to receive either subconjunctival injection of 0.25 mL of 5% TXA (TXA group, n = 25) or an equivalent volume of saline (control group, n = 25). Baseline characteristics, including age, gender, working environment, allergies, preoperative logMAR best-corrected visual acuity, and systemic anticoagulant or antiplatelet therapy, were similar between the groups. The primary outcome measures were intraoperative bleeding, surgery duration, and the number of eye spears used. Secondary outcome measures included postoperative visual acuity and pterygium recurrence rates at 3 years post-surgery. Results: No significant differences were observed between the TXA group and the control group in terms of surgery duration (445.3 ± 94.8 s vs. 423.5 ± 80.6 s, P = 0.40), the number of eye spears used (3.5 ± 2.4 vs. 3.5 ± 2.6, P = 0.97), or the weight of absorbed blood (1.94 ± 1.40 grams vs. 1.90 ± 1.25 grams, P = 0.91). Additionally, there were no significant differences in postoperative visual acuity (0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR, P = 0.39) or pterygium recurrence rates at 3 years post-surgery (8.0% vs. 4.4%, P = 0.60). Subconjunctival TXA injection was safe, with no reported adverse events or complications associated with its use. Conclusion: Subconjunctival injection of TXA did not significantly reduce intraoperative bleeding, shorten surgery duration, or improve postoperative outcomes in pterygium surgery. The intervention was safe and well-tolerated, but further research is warranted to explore alternative interventions or modifications to the surgical technique that may improve outcomes in pterygium surgery.

裸巩膜翼状胬肉手术联合使用丝裂霉素 C 和不使用氨甲环酸的持续时间:随机双盲对照试验。
目的:评估结膜下氨甲环酸(TXA)在翼状胬肉手术中减少术中出血、缩短手术时间和改善术后效果的效果。方法:在这项双盲随机对照试验中,接受翼状胬肉手术的 50 名患者的 50 只眼睛被随机分配到结膜下注射 0.25 mL 5%氨甲环酸(TXA 组,n = 25)或等量生理盐水(对照组,n = 25)。两组的基线特征相似,包括年龄、性别、工作环境、过敏史、术前最佳矫正视力 logMAR 值、全身抗凝剂或抗血小板治疗。主要结果指标为术中出血量、手术持续时间和使用的眼矛数量。次要结果指标包括术后视力和术后三年翼状胬肉复发率。结果:TXA组与对照组在手术时间(445.3 ± 94.8 秒 vs 423.5 ± 80.6 秒,P = 0.40)、眼矛使用数量(3.5 ± 2.4 vs 3.5 ± 2.6,P = 0.97)或吸收血液重量(1.94 ± 1.40 克 vs 1.90 ± 1.25 克,P = 0.91)方面无明显差异。此外,术后视力(0.14 ± 0.13 logMAR vs. 0.20 ± 0.19 logMAR,P = 0.39)或术后 3 年翼状胬肉复发率(8.0% vs. 4.4%,P = 0.60)均无明显差异。结膜下注射 TXA 是安全的,没有与使用 TXA 相关的不良事件或并发症报道。结论:结膜下注射 TXA 是安全的:结膜下注射 TXA 并不能明显减少翼状胬肉手术的术中出血、缩短手术时间或改善术后效果。该干预措施安全且耐受性良好,但仍需进一步研究,探索可改善翼状胬肉手术疗效的其他干预措施或手术技巧的改进方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.60
自引率
4.30%
发文量
72
审稿时长
1 months
期刊介绍: Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信